Entities / Company
Vanda Pharmaceuticals (United States).
company in Washington D.C., United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 15
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Vanda Pharmaceuticals appointed Kevin Moran to serve as CFO and Treasurer.Some support1 report
-
Vanda shares underperformed the market so far this year, based on events of July 31, 2025.Some support3 reports
-
Vanda Pharmaceuticals challenged the Food and Drug Administration's refusal to approve its drug Hetlioz, leading to a favorable ruling by the U.S. Court of Appeals for the D.C. Circuit on August 18, 2025.Some support2 reports
-
Vanda Pharmaceuticals participated in investor conferences held in New York City and Boston, while Wells Fargo hosted a conference in Boston.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Vanda Pharmaceuticals (United States) this week
News at the entities that move Vanda Pharmaceuticals (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Vanda Pharmaceuticals (United States)
-
Food and Drug Administration StructuralIn 2007, CBS broadcast featured Andrews, Cordes, and Couric criticizing the Food and Drug Administration's problems.Moves Vanda Pharmaceuticals (United States)
-
New York City Shared contextJoint entities are driving a high volume of General Obligation bond issuance in New York City.Moves Vanda Pharmaceuticals (United States)
Connections
The 4 strongest of 15, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kevin Moran Structural
Kevin Moran serves as the CFO and Treasurer for Vanda Pharmaceuticals.
-
FDA Structural
FDA regulates Vanda Pharmaceuticals' drug submissions and grants designations for its products.
-
Food and Drug Administration Structural
Vanda Pharmaceuticals' market viability is structurally dependent on regulatory decisions and approvals from the Food and Drug Administration.
-
New York City Shared context
Vanda Pharmaceuticals participates in summits and investor conferences held in New York City.
History
Events by the month they beganJune 2026
5 events- The FDA granted Orphan Drug Designation for VGT-1849B, a development involving Vanda Pharmaceuticals.
- Vanda Pharmaceuticals appointed Kevin Moran to serve as CFO and Treasurer.
- Vanda shares underperformed the market so far this year, based on events of July 31, 2025.
- Vanda Pharmaceuticals challenged the Food and Drug Administration's refusal to approve its drug Hetlioz, leading to a favorable ruling by the U.S. Court of Appeals for the D.C. Circuit on August 18, 2025.
- Vanda Pharmaceuticals participated in investor conferences held in New York City and Boston, while Wells Fargo hosted a conference in Boston.